Analysis of a volumetric-modulated arc therapy (VMAT) single phase prostate template as a class solution.
Prostate
Radiotherapy planning
Software
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
01
08
2018
revised:
26
09
2018
accepted:
28
10
2018
entrez:
4
12
2018
pubmed:
7
12
2018
medline:
7
12
2018
Statut:
ppublish
Résumé
To assess a class solution template for volumetric-modulated arc therapy (VMAT) for prostate cancer using plan analysis software. VMAT is a development of intensity-modulated radiotherapy (IMRT) with potential advantages for the delivery of radiotherapy (RT) in prostate cancer. Class solutions are increasingly used for facilitating RT planning. Plan analysis software provides an objective tool for evaluating class solutions. The class solution for VMAT was based on the current static field IMRT template. The plans of 77 prostate cancer patients were evaluated using a set of in-house plan quality metrics (scores) (PlanIQ™, Sun Nuclear Corporation). The metrics compared the class solution for VMAT planning with the IMRT template and the delivered clinical plan (CP). Eight metrics were associated with target coverage and ten with organs-at-risk (OAR). Individual metrics were summed and the combined scores were subjected to non-parametric analysis. The low-dose wash for both static IMRT and VMAT plans were evaluated using 40 Gy and 25 Gy isodose volumes. VMAT plans were of equal or better quality than the IMRT template and CP for target coverage (combined score) and OAR combined score. The 40 Gy isodose volume was marginally higher with VMAT than IMRT (4.9%) but lower than CP (-6.6%)( Automated VMAT planning for prostate cancer is feasible and the plans are equal to or better than the current IMRT class solution and the delivered clinical plan.
Sections du résumé
AIM
OBJECTIVE
To assess a class solution template for volumetric-modulated arc therapy (VMAT) for prostate cancer using plan analysis software.
BACKGROUND
BACKGROUND
VMAT is a development of intensity-modulated radiotherapy (IMRT) with potential advantages for the delivery of radiotherapy (RT) in prostate cancer. Class solutions are increasingly used for facilitating RT planning. Plan analysis software provides an objective tool for evaluating class solutions.
MATERIALS AND METHODS
METHODS
The class solution for VMAT was based on the current static field IMRT template. The plans of 77 prostate cancer patients were evaluated using a set of in-house plan quality metrics (scores) (PlanIQ™, Sun Nuclear Corporation). The metrics compared the class solution for VMAT planning with the IMRT template and the delivered clinical plan (CP). Eight metrics were associated with target coverage and ten with organs-at-risk (OAR). Individual metrics were summed and the combined scores were subjected to non-parametric analysis. The low-dose wash for both static IMRT and VMAT plans were evaluated using 40 Gy and 25 Gy isodose volumes.
RESULTS
RESULTS
VMAT plans were of equal or better quality than the IMRT template and CP for target coverage (combined score) and OAR combined score. The 40 Gy isodose volume was marginally higher with VMAT than IMRT (4.9%) but lower than CP (-6.6%)(
CONCLUSIONS
CONCLUSIONS
Automated VMAT planning for prostate cancer is feasible and the plans are equal to or better than the current IMRT class solution and the delivered clinical plan.
Identifiants
pubmed: 30505239
doi: 10.1016/j.rpor.2018.10.009
pii: S1507-1367(18)30152-4
pmc: PMC6251366
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92-96Références
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1456-62
pubmed: 19540062
J Appl Clin Med Phys. 2016 Nov 08;17(6):254-262
pubmed: 27929498
Onco Targets Ther. 2017 Jul 26;10:3755-3772
pubmed: 28794640
J Med Phys. 2016 Jul-Sep;41(3):162-8
pubmed: 27651562
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e657-62
pubmed: 22245189
Oncotarget. 2017 Aug 8;8(53):91174-91184
pubmed: 29207634
Rep Pract Oncol Radiother. 2016 Nov-Dec;21(6):567-570
pubmed: 27721671
Radiat Oncol. 2017 May 8;12(1):81
pubmed: 28482845
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):996-1001
pubmed: 18455326
Br J Radiol. 2011 Nov;84(1007):967-96
pubmed: 22011829
Strahlenther Onkol. 2018 Apr;194(4):333-342
pubmed: 29270648
Med Dosim. 2011 Winter;36(4):365-72
pubmed: 21377863
Jpn J Radiol. 2014 Apr;32(4):224-32
pubmed: 24510241
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):935-42
pubmed: 20044214
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):568-75
pubmed: 12243837
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1169-78
pubmed: 22704703
Strahlenther Onkol. 2016 Feb;192(2):109-17
pubmed: 26545764
Neoplasma. 2004;51(1):64-9
pubmed: 15004663
J Med Radiat Sci. 2013 Sep;60(3):84-92
pubmed: 26229615
Rep Pract Oncol Radiother. 2017 Nov-Dec;22(6):441-449
pubmed: 28883765